| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Jeong-Ho Seok | Q60618047 |
| P2093 | author name string | Changsu Han | |
| Chi-Un Pae | |||
| Soo-Jung Lee | |||
| Byung-Joo Ham | |||
| Ho-Jun Seo | |||
| Jong-Woo Paik | |||
| Hong Jin Jeon | |||
| Boung Chul Lee | |||
| Kyung-Phil Kwak | |||
| P2860 | cites work | An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. | Q51906231 |
| Residual symptoms after partial remission: an important outcome in depression | Q71095565 | ||
| Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association | Q73682867 | ||
| Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale | Q74249053 | ||
| Aripiprazole augmentation for treatment of patients with inadequate antidepressants response | Q79366637 | ||
| Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study | Q80207025 | ||
| Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability | Q81338893 | ||
| Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents | Q28307397 | ||
| The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) | Q29547223 | ||
| Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice | Q29614979 | ||
| Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis | Q29619093 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder | Q31121208 | ||
| Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission | Q33917532 | ||
| The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. | Q34004814 | ||
| How informative are open-label studies for youth with bipolar disorder? A meta-analysis comparing open-label versus randomized, placebo-controlled clinical trials | Q34095588 | ||
| Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. | Q34301067 | ||
| Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines | Q34590507 | ||
| An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression | Q34642676 | ||
| Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis | Q34645209 | ||
| Are SNRIs more effective than SSRIs? A review of the current state of the controversy. | Q34802899 | ||
| Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. | Q35142087 | ||
| Evaluating antidepressant therapies: remission as the optimal outcome | Q35557189 | ||
| Augmentation of antidepressants with atypical antipsychotics: a review of the current literature | Q37062820 | ||
| Understanding heterogeneity in meta-analysis: the role of meta-regression | Q37600940 | ||
| Innovations in clinical research design and conduct in psychiatry: shifting to pragmatic approaches | Q37666548 | ||
| Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder? | Q38008508 | ||
| Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial | Q38484092 | ||
| Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants | Q39304379 | ||
| Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: an open preliminary study. | Q42610470 | ||
| Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder | Q42672198 | ||
| Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder | Q42672211 | ||
| The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study | Q44627462 | ||
| Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study | Q45733394 | ||
| Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. | Q46002104 | ||
| An open study of aripiprazole and escitalopram for psychotic major depressive disorder | Q46164325 | ||
| Aripiprazole as an adjunctive treatment for refractory unipolar depression | Q46829213 | ||
| The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial | Q47239632 | ||
| Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study | Q48165057 | ||
| A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). | Q48742900 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | major depressive disorder | Q42844 |
| placebo | Q269829 | ||
| P304 | page(s) | 371-379 | |
| P577 | publication date | 2014-10-20 | |
| P1433 | published in | Psychiatry investigation | Q26853796 |
| P1476 | title | A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises | |
| P478 | volume | 11 |
| Q47890843 | "Salami Slicing" in Pooled Analyses of Second-Generation Antipsychotics for the Treatment of Depression |
| Q26797416 | Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice |
| Q38553417 | Why Systematic Review rather than Narrative Review? |
Search more.